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ABSTRACT
Human cytomegalovirus (HCMV) antigens in glioblastoma (GBM) present opportunities for personalised
immunotherapy. However, their presence in GBM tissue is still under debate, and evidence of their impact
on functional immune responses and prognosis is sparse. Here, we investigated the presence of pp65
(UL83) and immediate early 1 (IE-1) HCMV antigens in a cohort of Norwegian GBM patients (n D 177),
using qPCR, immunohistochemistry, and serology. HCMV status was then used to investigate whether viral
antigens influenced immune cell phenotype, infiltration, activation and patient survival. Pp65 and IE-1
were detected by qPCR in 23% and 43% of GBM patients, respectively. Furthermore, there was increased
seropositivity in GBM patients relative to donors (79% vs. 48%, respectively; Logistic regression, OR D 4.05,
95%CI [1.807-9.114], P D 0.001, also when adjusted for age (OR D 2.84, 95%CI [1.110-7.275], P D 0.029).
Tissue IE-1-positivity correlated with increased CD3CCD8C T-cell infiltration (P < 0.0001), where CD8C
effector memory T (TEM) cells accounted for the majority of CD8
CT cells compared with peripheral blood of
HCMVC patients (P < 0.0001), and HCMVC (P < 0.001) and HCMV¡ (P < 0.001) donors. HLA-A2/B8-
restricted HCMV-specific CD8C T cells were more frequent in blood and tumor of HCMVC GBM patients
compared with seronegative patients, and donors irrespective of their serostatus. In biopsies, the HCMV-
specific CD8C TEM cells highly expressed CTLA-4 and PD-1 immune checkpoint protein markers compared
with populations in peripheral blood (P < 0.001 and P < 0.0001), which expressed 3-fold greater levels of
CD28 (P < 0.001 and P < 0.0001). These peripheral blood T cells correspondingly secreted higher levels of
IFNg in response to pp65 and IE-1 peptide stimulation (P < 0.001). Thus, despite apparent increased
immunogenicity of HCMV compared with tumor antigens, the T cells were tolerised, and HCMV status did
not impact patient survival (Log Rank3.53 HR D 0.85 95%CI [0.564-1.290], P D 0.45). Enhancing immune






Glioblastoma (GBM) is the most frequent and malignant brain
tumor in adults.1 Despite aggressive multimodal treatment con-
sisting of surgery and concurrent temozolomide chemotherapy
with fractionated radiotherapy, median and 5-year survival of
patients remains dismally at 14.6 months and 9.8%,
respectively.2
One of the more promising approaches today is to identify
factors that drive immunogenicity of GBM. Such factors/antigens
may provide salient targets for novel and effective treatments,
particularly approaches for immunotherapy. The presence of
human cytomegalovirus (HCMV) in the GBM microenviron-
ment has generated considerable interest as viral antigens provide
unique targets for the development of immune targeted thera-
pies. HCMV is a member of the Herpesviridae family of double
stranded DNA viruses where primary infection usually occurs
during childhood in an asymptomatic manner, but thereafter the
virus remains latent in endothelial cells and mononuclear cells.3,4
HCMV also exhibits tropism for glial cells, thus, subsequent
detection in GBM tissues offers unique potential for therapeutic
targeting.
HCMV products have however, been variably demonstrated
in GBM.5-8 Some have disputed the existence of HCMV anti-
gens in the tumor at altogether.3,9,10 Several factors ostensibly
contribute to this discrepancy, including age, gender and socio-
economic status of the patients in these studies. The diverse
methods, targeted HCMV products and sample sizes analyzed
may also account for the variation, especially in the older publi-
cations. It has also been suggested that HCMV detection may
vary with time due to sample storage.11
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HCMV has a 235-kb genome that encodes approximately
200 proteins subdivided into 3 distinct regions: the repeat long
and short regions (RL and RS) and the unique long (UL) and
unique short (US) regions,12 many of which are not necessary
for viral replication.13 However, these proteins have been
shown to influence a broad spectrum of biologic functions,
including host cell telomerase activity, cellular differentiation,
apoptosis and even migration of tumor cells through RTK/Ras/
Phosphatidylinositol 3-kinase (PI3K)/AKT and GSK3-b signal-
ing. HCMV gene products interact with TP53, retinoblastoma
(Rb) and interfere with mismatch DNA repair to promote glio-
magenesis.14-18 Furthermore, US28, a homolog of the human
G-protein-coupled CCR1 chemokine receptor, was demon-
strated to localize near GBM vasculature,19 and induce IL-6
and COX-2 expression. This cascade of signalling events results
in the phosphorylation of signal transducer and activator of
transcription 3 (STAT3) and downstream production of pro-
angiogenic vascular endothelial growth factor (VEGF), which
all directly promote GBM progression.19-22
Indeed, GBM patients with low grade HCMV infection, indi-
cated by attenuated expression levels of immediate early-1 (IE-1)
antigen, were reported to have improved survival outcomes
compared with those with high-grade infection.23 The authors
reported that the impact of HCMV on patient survival was inde-
pendent of age; yet several studies have shown that high levels of
HCMV-specific IgG are associated with aging and likelihood of
reactivation24-26 and mortality.27 This discrepancy may be due to
poor correlation between HCMV seropositivity and presence of
viral gene products in tumor tissue.28,29 Nevertheless, the study
did not correct for O6 methylguanine DNA methyltransferase
(MGMT) a strong prognostic and predictive factor for response
to temozolomide chemotherapy30 which could have confounded
their findings. In a separate study, the authors treated HCMV
positive GBM patients with valganciclovir as add-on to standard
therapy and reported a 2-year survival extension up to 62%.23
Further studies are required to confirm therapeutic efficacy of
this drug.31 Thus, the impact of HCMV on patient survival has
not been unequivocally determined.
HCMV promotes malignant progression by inducing
tumor-supportive monocytes,6,20 and facilitating escape from
immune surveillance. Proteins and nucleic acids from US2,
US3, US6, USI0 and US11 were demonstrated to inhibit class I
human leukocyte antigen (HLA) expression, thus interfering
with antigen presentation to cytotoxic CD8C T lymphocytes.
Since virus-infected cells are the natural targets of CD8C and
CD4C T lymphocytes that recognize and eliminate viral pepti-
des presented on class I and II HLA, respectively, we hypothe-
sized that differential frequency of HCMV gene products in
GBM biopsies may impact T cell infiltration, function and sur-
vival outcomes. Thus, we aimed to demonstrate the presence of
pp65 and IE-1 HCMV products in blood and within the tumor
microenvironment in a large cohort of Norwegian GBM
patients (n D 177) and healthy blood donors (n D 91), using
several molecular methods (including qPCR, IHC and serol-
ogy) in blood and within the tumor microenvironment. We
investigated the influence of HCMV viral antigens on fre-
quency of T-cell effector and memory phenotypes in blood and
tumor, on T cell tumor infiltration, and function and whether
such changes could affect patient survival outcomes. The results
indicated that although systemic and localized immune milieus
are differentially affected by the presence of HCMV in patients,
they remain functionally tolerant to tumor cells. Thus, treat-
ment regimens that exploit both HCMV and tumor-antigen
specificity may be more effective but only in combination strat-
egies that simultaneously overcome tolerance in tumors.
Results
Detection of HCMV pp65 and IE-1 by qPCR and IHC in GBM
patient blood and matched tissue
The inconsistencies in reported HCMV prevalence in GBM
patients might be ascribed to differences in the detection sensi-
tivity between the various methods applied across studies. We
therefore used both DNA and protein based assays to detect
HCMV in patient biopsies and matching blood samples. PCR
was used first to detect the late antigen (UL83) pp65 and imme-
diate early-1 (IE-1) DNAs in patient samples. The late antigen
(UL83) pp65 DNA was detected in 16.4% (26/159) of tumors
but only in 10.1% (12/119) of the corresponding blood samples
(Fig. 1A, 1C and 1D). Immediate early -1 (IE-1) DNA was
detected in 37.8% (65/172) of tumors (Fig. 1D), and in 13.8%
(18/130) of patient blood samples.
In IHC, we found that IE-1 protein was expressed in 25.3%
(40/158) of the tumors. IE-1 expression was furthermore asso-
ciated with putative tumor and macrophage cells in the vicinity
of or within blood vessels (Fig. 1A, 1B and 1C). Flow cytometry
performed on cell suspensions from dissociated tissue samples
confirmed that pp65 was indeed expressed on various cell types
within tumor samples, including CD45brightCD11bbright macro-
phages, CD45dimCD11bbright microglia, CD45¡CD31C endo-
thelial cells and CD45¡ tumor cells (Fig. 1E and 1F).
Finally, analysis of all patient blood samples revealed that
79.2% (38/48) of GBM patients were HCMV IgG seropositive
(Fig. 1A) compared with 48.4% (44/91) of healthy Norwegian
donors (OR 4.05, 95% CI (1.807-9.114), P D 0.001). The 13-year
higher patient age only partially accounted for the variance (OR
2.84 95% CI [1.110-7.275], P D 0.029), indicating that there was
an inherent HCMV seropositivity risk associated with GBM.
Inter-method correlation of HCVM detection in GBM
To determine whether the variance in reported HCMV preva-
lence in GBM might be due to discrepancies between the meth-
ods used, we examined whether associations existed between
the methods applied here. We specifically wanted to determine
whether detection of IE-1 and pp65 DNA by qPCR were corre-
lated in blood and tumor samples, with each other, with IE-1
protein detected by IHC, or with HCMV IgG antibodies
detected in plasma by serology. In the first analysis, we found
no correlation between blood and tumor samples in patients
for either IE-1 or pp65 DNA results as determined by qPCR
(ChiSq2.11, P > 0.05, likewise, pp65 ChiSq 0.0004, P > 0.05;
Fig. 1D). Second, qPCR detected IE-1 was positively correlated
with qPCR detected pp65 DNA in blood and tumor samples of
patients (ChiSq 6.1, PD 0.01; Fig. 1C and 1D). However, neither
qPCR detected IE-1 nor pp65 correlated with IE-1 protein as
determined by IHC (P > 0.05). Third, a trend toward a






































significant association of qPCR detected IE-1 with IgG serology
was uncovered (ChiSq 3.8, P D 0.052; Fig 1C), whereas qPCR
detected pp65 was not correlated with IgG serology. Finally,
IE-1 protein detected by IHC was not correlated with serology,
IE-1 or pp65 DNA (P > 0.05). Together, these analyses demon-
strated that only qPCR detected IE-1 DNA was significantly
correlated with levels of pp65 DNA and indicated that qPCR
for IE-1, pp65 DNA and serology are reliable methods for
detecting HCMV positivity in GBM patients (Fig. 1C). More-
over, there was a greater likelihood of detecting IE-1 DNA in
samples more recently stored in liquid nitrogen in our tumor
bank during the consecutive years from 2009 to 2017 (Logistic
regression, OD1.19, CI [1.05-1.35], P D 0.008). This effect of time
was also significant when considering 2010 as the median cutoff
year (Logistic regression, OD3.07, CI [1.60-5.90], P D 0.001).
However, age of samples did not affect detection of pp65 DNA
in qPCR assays (Logistic regression, OD0.87, CI [0.74-1.02],
P D 0.087), even after considering the cutoff (Logistic regres-
sion, OD1.55, CI [0.70-3.43], P D 0.283).
Decreased CD3CCD4C T cells and increased NK cells
in GBM patient blood
Immune cell profiling in tumor and systemic circulation pro-
vides insight into the potential functionality of the immune
response in GBM patients compared with healthy donors, and
Figure 1. HCMV positivity in GBM determined comparatively by serology, qPCR and IHC. GBM patients were investigated for presence of HCMV pp65 and IE-1 expression
by (A) qPCR, IHC and serology (dark gray bars D positive samples and light gray bar D negative samples) and (B) IE-1 expression on macrophage/myeloid derived cells
(left panel) and on tumor cells (right panel). Magnification 400X, Scale bar 100 mm. (C) Venn diagram showing comparative HCMV serology (IgG), qPCR (pp65), qPCR (IE-
1) and IHC (IE-1) detection in GBM tissue and blood. (D) Venn diagram showing comparative HCMV pp65 and IE-1 qPCR in GBM patients’ blood and tumor. (E) Representa-
tive dotplots showing (left to right) macrophages (CD45brightCD11bbright) and microglia (CD45dimCD11bbright) within tumor biopsies cells; pp65 vs. CD45 within macro-
phages of tumor biopsies; pp65 vs. CD31 within CD45¡ tumor biopsy cells; and pp65 vs. CD45 within CD45¡ tumor biopsy cells. (F) % mean § SEM of pp65C cells within
CD45brightCD11bbright macrophages, CD45dimCD11bbright microglia, CD45-CD31C endothelial cells and CD45- tumor cells. (2-way ANOVA, Bonferroni’s multiple compari-







































ultimately whether differences might exist between HCMVC
and HCMV¡ patient populations. The distribution and
immune cell phenotypes was thus first examined without
regard to HCMV status in peripheral blood and tumor samples
from GBM patients and compared with that of peripheral
blood in normal healthy donors using flow cytometry. Firstly,
GBM patients exhibited attenuated numbers of CD3C T cells in
blood and tumor compared with healthy donors (2-way
ANOVA, GBM-blood 43.4 § 2.7%; tumor 44.0 § 5.4% vs. 67.1
§ 1.5%, P < 0.0001, Fig. S1A, 1B and 1D). Furthermore, GBM
patients had greater numbers of CD3¡CD56C NK cells in blood
(16.3 § 2.2%) but not in tumor (13 § 2.6%), compared with
peripheral blood of controls (7.6 § 0.7% 2-way ANOVA, P <
0.01; Fig. S1A, 1B and 1D). There was no difference in
CD3CCD56C subsets (Fig. S1D). GBM patients had decreased
numbers of T helper cell (Th) phenotype (CD4C subset) in
both peripheral blood and tumor compared with healthy con-
trols (2-way ANOVA, blood 57.9 § 2.3%; tumor 40 § 3.9% vs.
67.6§ 1.7%, P< 0.01 and P< 0.0001, respectively), but no dif-
ference in the numbers of cytotoxic T-lymphocytes (CTLs;
CD8C subset) was detected relative to healthy donors (Fig. S1C
and 1E). These results demonstrated diminished T-helper but
not cytotoxic T cells in GBM patients compared to healthy
individuals.
IE-1 positivity is associated with increased T cell infiltration
We next investigated whether the presence of HCMV-IE-1 and
-pp65 in the tumor microenvironment might correlate with dif-
ferential recruitment of T lymphocytes and NK cells into the
Figure 2. Decreased NK cells in blood and increased CD8C T cells in tumor of HCMVC patients. Representative IE-1C or IE-1¡ tumors determined by IHC showing (A) CD3
positivity and (B) CD8C T cell infiltration. Magnification 400X, Scale bar 100mm. (C) % mean § SEM of T cell (CD3C), Th cells (CD4C), CTLs (CD8C) and NK cells (NKp46C)
infiltrating the IE-1C or IE-1¡ tumors determined by IHC, nD 138. (D) % mean § SEM of CD3CT cells and CD3¡CD56C NK cells in peripheral blood of HCMVC and HCMV¡
GBM patients and donors determined by flow cytometry. (E) Representative dotplots showing CD4C vs. CD8C T cell populations in seropositive patient and healthy con-
trol donor. (F) % mean§ SEM of CD4C and CD8C T- cells in peripheral blood of HCMVC and HCMV¡ patients (nD 26) and donors (nD 56). Two Way ANOVA, Bonferroni’s
multiple comparison P < 0.05, P < 0.01, and P < 0.0001.






































tumor. IE-1 positivity determined by both IHC and qPCR was
correlated with increased CD3C T cell infiltration (IE-1 IHC:
ChiSq 16.22, P < 0.000; IE-1 qPCR ChiSq 9.4, P D 0.009; Fig. 2A
and 2C). Multiple comparisons were then performed with logis-
tic regression analyzing infiltration of CD3, CD4 and CD8
simultaneously. CD3 was positively associated with IE-1 protein
(Logistic regression 13.2 OR 1.07 95% CI [1.03-1.113], P< 0.001)
as was CD8 (Logistic regression 6.4 OR 1.095 95% CI [1.020-
1.746, P D 0.021). In multiple comparisons, CD8 accounted for
much of the variance (OR 1.069 95% CI [0.982-1.163], P D 0.11
of CD3 OR 1.056 95% CI [1.006- 1.107], P D 0.025) indicating
that IE-1C GBM tumors showed higher frequency of infiltrating
CD3CCD8C cytotoxic T cells (Fig. 2B and 2C). No difference in
CD3CCD4C T cell infiltration was detected in IE-1C and IE-1¡
tumors (P > 0.05), or NKp46C NK cells (P > 0.05; Fig. 2C). In
contrast, the presence of pp65 DNA determined by qPCR did
not significantly correlate with CD3C T cell infiltration (ChiSq
1.04, PD 0.6) or NKp46C NK cell infiltration (Chisq 2.63, PD 0.3,
data not shown). In peripheral blood, HCMVC GBM patients
had significantly less CD3CCD4CT cells compared with healthy
donors regardless of serological status (2-way ANOVA, P <
0.05 and P < 0.01, Fig. 2D, 2E and 2F). HCMV¡ GBM patients
had more NK cells in peripheral blood than healthy controls
regardless of HCMV status (P < 0.01, Fig. 2D). Taken together,
tumor-derived suppression attenuated NK and CD4C T cells in
tumor and blood of patients regardless of HCMV status. In con-
trast, the presence of HCMV products correlated with increased
tumor infiltration of CD8C cytotoxic T cells.
Diminished CD4C TN cells and increased CD8C TEM cells
in peripheral blood and tumor of HCMV seropositive
patients compared with normal healthy donors
To further understand the selective T cell tumor infiltration, we
analyzed the phenotypes of the CD4C and CD8C T cells in
blood and tumor of GBM patients and compared these to the
blood of healthy donors. HCMVC patients had significantly
diminished CD45RO¡CD62LCCCR7bright CD4C TN cells in
tumor compared with both seronegative and seropositive
donors (2-way ANOVA, P < 0.0001 for both analyses) and in
blood compared with seronegative and seropositive donors
(2-way ANOVA, P < 0.001 and P < 0.05, respectively; Fig. 3A,
3B, 3C and 3D, Table 3), but not compared with seronegative
tumors. Likewise, the tumor tissue of HCMVC patients con-
tained significantly higher CD45ROCCD62L¡CCR7low
CD4CTEM cells compared with peripheral blood of seropositive
and seronegative donors (2-way ANOVA, P < 0.0001 for both)
as well as blood of seropositive and seronegative patients (P <
0.01 for both; Fig. 3A, 3B, 3C and 3D, Table 3). There was also
no difference in CD45RO¡CD62L¡ CCR7low CD4CTE cells
and CD45ROCCD62LC CCR7bright CD4CTCM cells (2-way
ANOVA, P > 0.05; Fig. 3A, 3B, 3C and 3D, Table 3). Thus, the
decreased TN and increased TEM CD4
C cells in the GBM
patients were not dependent on HCMV serostatus and might
be a result of generalized tumor suppression.
Seronegative donors exhibited the greatest frequencies of
CD8CTN cells in peripheral blood compared with both HCMVC
and HCMV¡ tumors (P < 0.001 and P < 0.01, respectively;
Fig. 3A, 3B, 3C and 3E, Table 3) and may imply a healthy and
more functional immune system. CD8CTEM cells also accumu-
lated substantially in tumor tissue compared with peripheral
blood of seropositive GBM patients, (P< 0.0001) as well as both
seropositive and seronegative donors (P < 0.001 and P <
0.0001, respectively; Fig. 3A, 3B, 3C and 3E, Table 3). All TE and
TEM cells expressed lower levels of CCR7 compared with TN and
TCM cells, respectively (Fig. 3F and 3G). Taken together, differ-
ences in T cell phenotypes indicated a tumor directed matura-
tion effect rather than an effect of HCMV serostatus.
Tumor-derived TEM cells express less CD28 but more
CTLA-4 than TEM cells in peripheral blood of HCMV
C
patients
The potential functionality of T cell responses in various dis-
eases can be reliably determined by examining molecular
markers that have been associated with activation. We thus
sought to investigate whether the activation states of the CD4C
and CD8C TEM subsets differed with regard to HCMV seropos-
itivity in patient tumor and blood, compared with healthy
donors, by characterizing expression of immune checkpoint
markers CD28, CTLA-4 and PD-1. Peripheral blood-derived
CD4CTEM cells from HCMVC patients highly expressed CD28
compared with tumor-derived CD4CTEM cells from HCMVC
patients (2-way ANOVA, P < 0.01, Fig 3H). These patient-
derived cells also expressed CD28 at levels that were 2-fold
greater than CTLA-4 potentially indicating greater activation
status (Fig. 3H and 3I). In HCMV¡ patients, CD4CTEM cells
from the blood expressed CD28 but only barely detectable lev-
els of the immune checkpoint marker CTLA-4 (Fig. 3H and
3I), indicating greater functionality of peripheral blood cells
than those within the tumor microenvironment.
For CD8C subsets,greater levels of CD28 were observed in
peripheral blood-derived CD8CTEM cells from HCMVC GBM
patients (P < 0.0001), as well as HCMVC (P < 0.0001) and
HCMV¡ (P < 0.001) donors, compared with HCMVC tumor-
derived CD8CTEM cells (2-way ANOVA, Fig. 3J). In contrast,
the HCMVC tumor-derived CD8CTEM cells expressed greater
levels of CTLA-4 than in those from peripheral blood of
HCMVC patients (P < 0.01, Fig. 3K). Moreover, an increased
percentage of CD8CTEM cells in tumor expressed CTLA-4 com-
pared with blood of HCMVC patients (P < 0.0001), as well as
HCMVC (P < 0.0001) and HCMV¡ donors (P < 0.001) (2-
way ANOVA, Fig. 3L). Collectively, these data may indicate a
status of tumor-derived suppression of T cell activation, char-
acterized by decreased CD28 and increased CTLA-4.
CTLA-4 checkpoint blockade and CD8CTEM function
Despite increased fractions of CD8CTEM in HCMVC patient
tumors (Fig. 3E) with elevated expression of CTLA-4 (Fig. 3K
and 3L) and PD-1 (Fig. 4A and 4B), these T cells from HCMVC
GBM patient tumors degranulated better under steady-state
compared with blood-bourne T cells from HCMVC GBM
patients (P < 0.0001), as well HCMVC (P < 0.0001) and
HCMV¡ donors (P < 0.0001; Fig. 4A and 4B). Anti-CTLA-4
blockade in combination with HCMV-specific peptide stimula-
tion of both tumor and peripheral blood T cells from patients







































capacity (data not shown). However, low IFNg secreting T cells
from the blood of HCMVC patients showed a non-significant
tendency toward increased IFNg levels after CTLA-4 check-
point blockade (69.3 § 26.9 vs. 332.1 § 200.3, baseline vs.
blockade, respectively; Fig. 4C and 4D) before stimulation of
HCMV peptides. Likewise, non-statistically significant changes
in IFNg release were also observed in donor T cells after
CTLA-4 checkpoint blockade (158 § 88.9 vs. 463.4 § 249.1,
baseline vs. blockade, respectively; Fig. 4C and 4D). Taken
together, these results indicated that CD8CTEM infiltrating the
tumor are tolerised to express high levels of CTLA-4 and PD-1
immune checkpoint molecules and diminished CD28, despite
greater propensity for degranulation. Anti-CTLA-4 blockade
was not sufficient to relinquish their immunosuppression,
whereas in corresponding peripheral blood T-cells cells, this
treatment showed a tendency toward harnessed responses.
Increased pp65-HLA-A2/B8 dextramer restricted CD8CT
cells in GBM tumor
Given the lack effect of HCMV on either T cell phenotype or
function, we next asked whether the CD8CTEM cells infiltrating
Figure 3. Increased CD4C and CD8C TEM cells in HCMVC GBM tumor with higher CTLA4/CD28 ratio compared with donor peripheral blood. (A) Representative dotplots
showing lymphocytes in dissociated GBM tumor gated on FSC vs. SSC; singlets, live dead and within CD45C cells, left to right. Representative dotplots showing (B) CD4C
(Th) vs. CD8C (CTLs) T cell populations and (C) CD45RO vs. CD62L populations within the Th cell and CTL gates. % mean § SEM of (D) Th (CD3CCD4C) and (E) CTLs
(CD3CCD8C) na€ıve (N: CD45RO¡CD62LCCCR7bright), central memory (CM: CD45ROCCD62LCCCR7bright), effector (E: CD45RO¡CD62L¡CCR7low) and effector memory (EM:
CD45ROCCD62L¡CCR7low) in peripheral blood (n D 22) and tumor (n D 19) of HCMVC and HCMV¡ patients compared with seropositive vs. seroponegative donors
(n D 16) (Two way ANOVA, Bonferroni’s multiple comparison P < 0.05, P < 0.01, P < 0.001 and P < 0.0001). Mean MFI § SEM of CCR7 within (F) the Th
(CD3CCD4C)and (G) CTLs (CD3CCD8C) T cell subsets, showing low CCR7 expression in TEM and TE subsets (Two way ANOVA, Bonferroni’s multiple comparison,
P < 0.05,
and P < 0.0001). Mean MFI § SEM of (H) CD28 and (I) CTLA-4 within the Th (CD3CCD4C)TEM; (J) CD28 and (K) CTLA-4 within the CTLs (CD3CCD8C)TEM (Two way
ANOVA, Bonferroni’s multiple comparison, P<0.01, P < 0.001 and P < 0.0001). (L) % mean § SEM of CTLA-4C cells within the CTLs (CD3CCD8C)TEM (Two way
ANOVA, Bonferroni’s multiple comparison, P < 0.001 and P < 0.0001).






































tumor and peripheral blood were in fact HCMV-specific, and
second, if they were functional in response to HCMV peptide
stimulation given the elevated fractions expressing CTLA-4.
Based on detection in tumor samples, 38.5% (5/13) of HCMVC
GBM patients exhibited HCMV-specific CD8CTEM cells in
tumor (Fig. 5C and 5D). However, the frequency of the HCMV-
specific CD8CTEM cells was greatest in the blood of seropositive
patients (6.0 § 1.6% cells) compared with seronegative patients
(0.4 § 0.2%; P < 0.01 cells) and healthy control donors regard-
less of serostatus (HCMVC:2.4 § 0.4%, P < 0.05; HCMV¡:0.01
§ 0.01%, P < 0.001, 2-way ANOVA, Fig. 5A, and 5B). Further-
more, 55.6% (5/9) of seropositive donors had detectable HLA-
A2/B8 restricted HCMV-specific CD8C T cells whereas only
15.8% (3/19) of GBM patients had these fractions in their blood
Figure 5. Increased HCMV-specific CD8C T-lymphocytes with reduced function in HCMVC GBM. (A) Representative dotplots showing HLA-A2/B8 dextramer restricted
pp65- and IE-1 specific CD8C T cell populations. (B) % mean § SEM of HLA-A2/B8 dextramerC CD8C T-cells and (C) bar graph showing frequency of samples containing
HLA-A2/B8 dextramer HCMV-specific CD8C T cells in HCMVC and HCMV¡ patients’ blood (n D 21), tumor (n D 15) and healthy donors’ blood (n D 16). (D) Live cell confo-
cal microscopy images visualizing HLA-A2/B8 dextramerC HCMV-specific CD8C T cells in GBM dissociated tissue from HCMVC vs. HCMV¡ patients, Magnification 630X,
scale bar 10 mm. (E) Representative IFNg ELISpots from seropositive vs. seronegative patients’ blood, tumor and healthy donors with and without stimulation with pp65
or IE-1 HCMV peptides. IFNg secretion was considered positive when number of cells secreting was  0 total cells. (F) % mean § SEM of IFNg secreting cells/106 total
cells after stimulation with pp65 or IE-1 HCMV peptides in HCMVC patients (n D 14) vs. HCMVC and HCMV¡ donors (n D 16). Low IFNg secretion  8; High
IFNg secretion 150 per 106 total cells. (G) Frequency of GBM patients and donors samples containing IFNg secreting cells after stimulation with pp65 or IE-1 HCMV pep-
tides in HCMVC patients (n D 14) vs. HCMVC and HCMV¡ donors (n D 16).
Figure 4. High CD107a degranulation and PD-1 expression in CD8 (T) cell from HCMVC patient biopsies. (A) % mean § SEM of CD107a and PD-1 expression in HCMVC
and HCMV¡ patients’ (n D 8), tumor (n D 6) and healthy donors’ (n D 8) CD3CCD8C T cells. (B) Representative dotplots and % mean § SEM of CD3CCD8C T cell express-
ing CD107a cells and PD-1 cells. (C) Representative IFNg ELISpots from seropositive vs. seronegative patients’ blood, tumor and healthy donors with and without stimula-
tion with pp65 or IE-1 HCMV peptides and with (C) or without (-) anti-CTLA-4 blockade. Secretion was considered positive when number of cells secreting was >0,
normalized to HCMV¡ donors. (D) Difference in frequency of IFNg secreting cells after stimulation with pp65 HCMV peptides in HCMVC patients (n D 5) vs. HCMVC







































(Fig. 5C). Finally, pp65-HLA-A2/B8 dextramer positive
CD8CCD3CCD56C cytotoxic cells were also detected exclusively
in tumor tissue. As expected seronegative donors and patients
reproducibly lacked these fractions (data not shown).
Secretion of IFNg as determined in ELISpot assays was used
to assess whether peptide stimulated T cells isolated from
HCMVC patients and/or donor samples were functional. None
of the HCMV¡ donors released IFNg in response to HCMV
peptide stimulation. Therefore, IFNg secretion was considered
positive when the number of cells secreting IFNg was > 0.
However, in response to stimulation with HLA-A2/B8
restricted IE-1/pp65 peptides, blood-derived T cells from sero-
positive patients secreted 4-fold more IFNg compared with
seropositive donor T cells (2-way ANOVA, P < 0.0001; Fig. 5E
and 5F). In response to IE-1/pp65 peptide stimulation, 87.5%
(7/8) of HCMVC donor blood samples released IFNg com-
pared with 78.6% (11/14) HCMVC patient blood samples
(Fig. 5G). In contrast, T cells from GBM tissues did not secrete
detectable levels of IFNg in response to IE-1/pp65 -peptide
stimulation (Fig. 5E). As expected, peptide stimulated blood-
derived T cells from HCMV¡ donors and patients did not
secrete IFNg (Fig. 5E and 5F). These results indicated that
although CD8CTEM cells infiltrating the HCMVC tumor were
HCMV specific, they were more functionally impaired that
those in peripheral blood.
IE-1 positivity has no impact on patient survival
Finally, to determine whether HCMV antigens might impact
disease progression, Kaplan-Meier curves for patient survival
were generated and also for evaluating impact of age and
MGMT promoter methylation status, 2 well-described prog-
nostic factors in GBM. The presence of HCMV antigens in the
tumor did not impact patient survival (Log Rank 0.51 HR D
0.845 95%CI (0.530-1.350), P D 0.48, Fig. S1F). However, age
(Log Rank7.97HR D 1.733 95% CI (1.181-1.2.540), P D 0.005,
data not shown) and MGMT promoter methylation (Log
Rank10.66 HR D 1.474, 95% CI (1.165-1.864), P D 0.001,
Fig. S1G) were prognostic as expected, confirming the validity
of our analyses.
Discussion
Contradicting evidence on the prevalence of HCMV gene prod-
ucts in GBM has been reported. Studies that contribute to clarify-
ing the controversy and elucidate the biologic impact of HCMV
in GBM tissues are important as the viral products may serve as
targets for effective immunotherapy for GBM patients. On the
other hand, active HCMV replication in GBM tissue may stymie
immunotherapeutic attempts thorough various immunoevasive
strategies,32-34 so that striking an intricate equilibrium of immune
activation is needed. Here, we report for the first time a compre-
hensive analysis of the HCMV status in a large cohort of GBM
tissues (n D 177), wherein n D 117 tumor-blood paired analyses
were conducted for pp65 and n D 78 paired analyses for IE-1, as
well as comparative serology analyses from (n D 48) patients and
(n D 91) healthy donors. We confirmed the presence of HCMV
products in 25 – 43% of GBM tissues, with 79% of GBM patients
being seropositive. These results are concordant with previously
reported prevalence.5,35-37 We determined that both serology and
qPCR were reliable methods to detect HCMV, where DNA, in
particular IE-1, was best correlated in blood and tissue by qPCR.
Nevertheless, IE-1 DNA was vulnerable to degradation over
time, confirming a previous suggestion.11 Serology detected more
patients who had been infected with HCMV than IHC or qPCR,
and reliably correlated with T cell responses and functional sta-
tus, which however were not associated with enhanced patient
survival. However, limited numbers of HCMVseronegative GBM
samples influenced the statistical power of our analyses as nearly
all GBM samples available for functional analyses were
seropositive.
Our study is the first to investigate TEM subsets in relation to
HCMV antigens in brain tumor tissue under steady-state and
how their phenotype impacts functional responses to HCMV
peptide stimulation. Our findings highlight the ultimate barrier
the tumor microenvironment represents in regulating T cell
responses against target cells expressing viral proteins.
Other studies reported higher IE-1 antigen levels in GBM
tissue than our finding, herein of 43%,5,36,38 with the exception
of one study35 where the antigen was detected at lower fre-
quency. The discrepancy may be attributed to the methods
used, but also to the relatively small number of previously
examined samples in individual studies, where the median case
number was n D 36 (range 21- 49). We also established that
pp65 was expressed on diverse cell types within the tumor envi-
ronment, including tumor cells, CD31C endothelial cells,
CD45brightCD11bright macrophages and CD45dimCD11bbright
microglial cells. Within the tumor compartment, approxi-
mately 20% of cells expressed pp65. It has been reported that
HCMV displays tropism for cancer stem cells and tumor asso-
ciated macrophages/microglia (TAMs) within GBM,6 where
TAMs are the predominant immune cells accounting for up to
40% of the tumor mass.39 HCMV attachment has been shown
to lead to polarization of TAMs to M2 anti-inflammatory phe-
notypes characterized by secretion of IL-10, arginase and iNOS
and increased STAT3 signaling to promote immunosuppres-
sion,6 through induction of PD-L1 on tumor cells, T cell anergy
or inhibition through nitric oxide signaling.40 Our data do con-
firm greater tropism of pp66 to macrophages, microglia and
endothelial cells than tumor cells.
The central tenet of host defense against viral infection pos-
its that CD8C T cells are instrumental,41 and that na€ıve CD8C
T cells proliferate and differentiate into effector phenotypes
upon encounter with antigen presented on class I HLA by den-
dritic cells in secondary lymphoid organs.41,42 Effector CD8C T
cells migrate into sites of infection and kill infected cells, and
upon clearance of infection, the population contracts, while a
pool of pathogen-specific memory CD8C T cells emerges and
persists long-term,43,44 allowing for more rapid expansion and
recall upon re-encounter with the same pathogen.45 Our results
demonstrated that CD3CCD8CT cells were increased in both
tumor tissue and blood of IE-1C seropositive GBM patients. In
blood, seropositive GBM patients displayed decreased levels of
CD4CT cells, a finding that concurs with previous reports in
elderly seropositive individuals denoting an “immune risk”
phenotype associated with increased morbidity and mortality.46
Within the CD4CT cell fractions, it was particularly the
CD45RO¡CD62LCCCR7bright TN cells that were attenuated in






































the tumor and blood, while CD45ROCCD62L¡CCR7low TEM
subsets were increased in the GBM tumor compared with
HCMV seropositive and seronegative donor and patient blood.
The engagement of the TCR on TN cells with HCMV-antigen
presented on class II HLA- molecules of antigen presenting
cells in secondary lymphoid organs results in T cell differentia-
tion to antigen experienced TE cells, potentially explaining their
loss from peripheral blood and their enrichment in non-lym-
phoid, tumor tissues. The limited data from seronegative GBM
patients for comparison, however, was a major limitation of
our study that prevented unequivocal conclusions regarding
the contribution of HCMV to the immune responses apart
from the generalized tumor immune suppression. In response
to pp65/IE-1 peptide stimulation, the HCMV specific
CD8CTEM cells in peripheral blood of patients produced IFNg
at 4-fold higher levels compared with healthy donors. These
cells highly expressed CD28 co-stimulatory molecules and
attenuated CTLA-4 levels, which is consistent with their
improved functionality. However, checkpoint blockade using
antibodies against CTLA-4 after stimulation with pp65/IE-1
HCMV peptides in HCMVC patients and donors did not sig-
nificantly alter the frequency of IFNg secreting cells or their
function in terms of degranulation or TNFa secretion. Since we
also observed increased basal expression levels of PD-1 on
CD8CTEM cells in the HCMVC patient biopsies, it may have
been instrumental to also block PD-1 in combination with
CTLA-4. The antibodies used were also not of clinical grade,
which may have influenced the sensitivity of our readout.
Previous studies demonstrated that CTLA-4 blockade
increased IL-2 production by CD4CT-helper cells resulting in
greater terminal differentiation of CD8CT cells and augmenta-
tion of antigen specific CD8CT cells capable of producing pro-
inflammatory cytokines IFNg and TNFa.47 Nevertheless, we
rarely detected HCMV antigens in blood, perhaps explaining
the greater amplitude of IFNg responses to exogenous pp65/
IE-1 peptide stimulation. In contrast, HCMV specific
CD8CTEM cells were more frequent in the tumor of HCMV
positive patients. Since by definition, these cells lack homing
and chemokine receptors CD62L and CCR7, it is possible that
their increased numbers in the tumor microenvironment is a
result of in situ proliferation in response to HCMV antigens
pp65 and IE-1 that were detected. The high numbers of CD56C
HCMV-specific CTLs in the GBM tumors reported herein
might also corroborate this hypothesis. Indeed, increased pro-
portions of HCMV-specific CD8CCD56C T cells have previ-
ously been described to be associated with primary or
reactivating HCMV infections.48,49 These CD56C T cells are
cytotoxic to HCMV infected tumor cells and express distinct
KIR, DNAM-1 receptors and a transcriptional gene signature
that is unique from NK cells and Va24CVb11C invariant
NKT.50,51 An alternative explanation for the source of these
cells is that they were not recruited from peripheral blood, but
indeed, expanded from CD103C resident T cells. Unfortu-
nately, we did not explore this possibility due to limited fresh
biopsy material. Nevertheless, pp65-specific antigen stimula-
tion of the TEM cells present in the tumor microenvironment
did not result in detectable IFNg production. It is possible that
the presence of a low-level of HCMV antigens in the tumor
microenvironment induced an exhausted phenotype in the
CD8CTEM cells. However, in the absence of HCMV¡ tumor
samples for comparison, it cannot be ruled out as a generalized
tumor induced immunosuppression. As a result, the tumor-
infiltrating HCMV-specific TEM cells exhibited greater CTLA-4
levels, and % of CTLA-4C populations compared with CD28
expression, as well as % of CD8CPD-1C fractions. CTLA-4 is
preferentially induced on activated CD4CT cells52 during the
priming phases of T cell activation, while PD-1 functions dur-
ing the effector phases of T cell surveillance in peripheral tis-
sues.53,54 Indeed, PD-1 expression is increasingly identified as a
hallmark of over activated T cells that have experienced high
antigen levels, extended periods of stimulation or exhausted
cells after reduced CD4CT cell help.55 This tenet would partially
support our reported findings here.
The precise molecular mechanisms for HCMV-specific
immune dysfunction that we had set out to decipher still
remain elusive, and in the absence of further evidence, the con-
clusion must be that generalized immune suppressive environ-
ment in GBM56,57 is a contributing factor that cannot be ruled
out. A previous study reported diminished numbers of pp65-
specific T cells in peripheral blood of GBM patients relative to
healthy donors, while yet another found no difference between
patients and controls.38,58 In both studies, however, T cells
from both patients and controls could be expanded to high
yields under continuous peptide stimulation in vitro. Expansion
under stimulation improved their functionality, as indicated by
their augmented killing of peptide-pulsed autologous cells as
targets and the production of a broader range of cytokines.
Based on such findings, immunotherapies based on HCMV
immunogenicity have already moved into the clinic. Adoptive
transfer of ex vivo expanded, peripheral blood-derived
HCMV¡specific T cells in combination with chemotherapy was
recently reported in 13 of 19 recurrent GBM patients. 11 of these
patients received up to 4 T-cell infusions, and the treatment was
well tolerated with long progression free survival reported.20,58
Expression analyses of the expanded T cells revealed a gene tran-
scription profile, upregulated IFNg with attenuated CTLA-4 and
FoxP3, that distinguished responding from non-responding
patients.20 Our results at steady-state are consistent with these
findings, and extend the knowledge by comparing tumor with
peripheral blood from GBM patients to healthy controls. Our
results lend support to the rationale for intra-tumoral /ventricular
adoptive transfer of expanded, functional antigen specific T cells
in combination with multiple immune checkpoint blockade strat-
egies and or other immunomodulation therapies, such as vaccine
therapy. Whether HCMV specific antigens have potential in this
context remains to be elucidated. Indeed, CTLA-4 immune
checkpoint inhibiting antibodies such as Ipilimumab have dem-
onstrated unprecedented efficacy as combination therapy in sub-
sets of patients with metastatic melanoma.59-61 The treatment
increased activated and antigen specific CD4C and CD8CT cells
with corresponding decrease in na€ıve CD4C and CD8CT cells.61,62
More recently, combination therapy of CTLA-4 and PD-1 block-
ade has improved survival and progression-free survival of
patients with metastatic melanoma with durable responses
beyond 3 y for a subset of patients.60,63,64 The presence of HCMV
antigens in the tumor microenvironment may ensure continued
proliferation, maturation and survival of the transferred cells.







































functionality as opposed to exhaustion. Thus, our findings pave
the way for intensive exploration as therapeutic strategy.
Although we have largely focused on adaptive immunity in
HCMVC GBM, cell types involved in innate immunity were
also detectably altered. In blood of HCMV seropositive
patients, NK cells were markedly reduced compared with sero-
negative patients and healthy donors regardless of HCMV sta-
tus. HCMV permanently reconfigures the NK-cell
compartment, a hallmark of which is greater frequency of
mature NK-cells characterized by expression of
CD57CCD16CCD94/NKG2C and inhibitory killer immuno-
globulin-like receptors (iKIR).65 We recently demonstrated that
GBM had a differentiating effect on NK cells indicated by
higher fractions expressing CD57, CD16 and NKG2D in GBM
patients that was further augmented by HCMV infection.66
The CD57C mature NK cells are potent killers but exhibit repli-
cative senescence and diminished proliferation67 possibly
explaining their reduced numbers in the blood of seropositive
GBM patients. HCMV proteins inhibit class I HLA expres-
sion32-34 that would result in loss of engagement of iKIRs spe-
cific for class I HLA ligands, effectively lowering the threshold
for NK-cell activation against infected cells.65 Indeed, seroposi-
tive GBM patients carrying the activating KIR2DS400101 allele
in the context of specific HLA-C1/C2 ligands had increased
HCMV matured NK cells with conceivably potent cytotoxicity
that contributed to substantially attenuated disease progres-
sion.66 Thus, under these conditions, NK cells can also contrib-
ute to killing HCMV infected tumor cells, especially if tagged
by anti-HCMV IgG. Their activation may contribute to the
release of IFNg that has potential to reverse the tumor micro-
environment from immunosuppressive to pro-inflammatory.
Despite increased T cell infiltration to the HCMVC tumors,
we were unable to demonstrate a survival benefit of HCMV
infection on patient outcomes. This is in contrast to a study
reporting that GBM patients with low-grade IE-1 expression
(cut-off at < 25% infected tumor cells) exhibited longer median
survival independent of age.68 With a much larger patient cohort,
we could not corroborate these findings. Differing methods of
stratification of HCMV positivity potentially account for the dis-
crepancy. The diminished T-cell functionality in the tumor
microenvironment likely underscores the lack of survival benefit
of HCMV antigens per se in our study. Nevertheless, another
large prospective study of (n D 347) leukemia patients could not
demonstrate prognostic effect of HCMV status based on serol-
ogy.26 Taken together, our findings support the recent surge of
interest in administering ex vivo expanded autologous antigen-
specific T cells or the use of tumor lysate pulsed dendritic cells
for immunotherapy against GBM. It will be important to com-
bine these cells with immunomodulating drugs or HCMV-spe-
cific vaccines to increase T and NK cell persistence and
functionality at the severely immunosuppressive tumor frontier.
Materials and methods
Ethics statement
The regional ethical committee approved the study (REK vest
013.09/20879; 2014/588), and samples were collected with the
informed consent of patients and healthy donors.
Norwegian GBM patients and healthy donors
GBM biopsies (n D 177) were analyzed wherein matching
tumor-blood samples were analyzed for pp65 (n D 117) and
IE-1 (nD 78). Samples were obtained during surgical resections
performed at Haukeland University Hospital, (Bergen, Nor-
way) between 1998 and 2017. Neuropathologists confirmed the
diagnosis of GBM. Plasma from healthy donors (n D 91) was
used for control experiments. Eligibility criteria for patient
material were the following: biopsies obtained at primary GBM
diagnosis, < 30% necrosis, and availability of follow-up data.
Survival was determined as time elapsed from the date of sur-
gery to death or last follow-up in July 2016.
GBM tissue dissociation and live cell confocal microscopy
Fresh biopsy tissue (n D 19) was mechanically diced with scal-
pels into pieces < 1 mm3 under sterile conditions. The tissue
was dissociated into single-cell suspensions in 5% Liberase DH
(5401089001, Roche Molecular Diagnostics; Pleasanton, CA,
USA) and 2% deoxyribonuclease I (LS002139, Worthington) in
HBSS (Gibco, 14170-088, Thermo Fisher Scientific; Waltham,
MA, USA) at 37C for 30 min in a shaking water bath at 220
strokes/min, through successive rounds. Cells were triturated,
filtered through a 100 mm cell strainer (352360, BD Falcon),
and centrifuged at 900 rpm for 5 min for harvesting. Cell filter-
ing was repeated once over a 70 mm cell strainer (352350, BD
Falcon) followed by twice over 40 mm filters (352340, BD Fal-
con). Live cell imaging was performed simultaneously with
dextramer analysis and T-cell phenotyping. A 10 mL drop con-
sisting of 50,000 GBM cells, stained with PE-conjugated HLA-
A2 or HLA-B8 dextramer, was seeded onto a Nunc Lab-Tek II
4-well chambered coverglass (154917, Thermo Fisher Scien-
tific). A Leica HCS PL Apo CS 63 £ numeric aperture
(1um1.4) oil objective was used, and live cell imaging was per-
formed using the Leica SP5 AOBS confocal microscope (Leica
Microsystems; Wetzlar, Germany). Images were imported and
compiled into figure montages with Adobe Photoshop software
(Adobe Systems; San Jose, CA, USA).
DNA isolation and quantitative PCR (qPCR)
Genomic DNA was isolated from blood and snap frozen, cryo-
sectioned GBM biopsies using the DNeasy Blood & Tissue Kit
(69504, QIAGEN), according to the manufacturer’s protocol.
Percentage of tumor cells in GBM cryosections was assessed at
> 70% based on H&E staining. To detect UL83 (pp65) and
major immediate early-1 (IE-1) sequences, qPCR was performed
on genomic DNAs with the QuantiTect SYBR green PCR kit
solution (204141, BioRad Laboratories, Inc.; Hercules, CA, USA)
in microcapillary plates in the Light-Cycler 480 System (Roche
Diagnostics; Indianapolis, IN, USA), following the manufac-
turer’s instructions. For PCR, a 5 min denaturation at 95C was
followed by 40 cycles of 10 s at 95C, 40 s at 56C for pp65 and
60C for IE-1 and 30 s at 40C. Sequences of primer pairs used
in qPCR were the following: UL83 (pp65) forward, 50- GCAGC-
CACGGGATCGTACT-30 and reverse, 50-GGCTTTTACCTCA-
CACGAGCATT-3069,70; IE-1 forward, 50-GACTAGTGTGATGC
TGGCCAAG-30 and reverse, 50-GCTACAATAGCCTCTTCC






































TCATCTG-30.3,71 DNA isolated from plasma from an HCMV-
infected patient sample was used as the positive control. pp65
and IE-1 were considered positive at Ct values  34.
HLA genotyping
The HLA class I locus (A, B, and C) in blood samples of GBM
patients and healthy donors was genotyped within 4-digit reso-
lution using sequence-specific oligonucleotide probe hybridiza-
tion (ProImmune; Table 1).
CMV serology
Plasma from GBM patients (n D 48) and healthy donors (n D
91) was serotyped for CMV specific IgG (6C15) and IgM
(6C16) antibodies using ARCHITECT CMV assays (Abbott;
Chicago, IL, USA). A clinical diagnostic cut-off for seropositiv-
ity was designated as IgG (Au/mL)  6 and IgM (index)  1
(Table 1).
Immunohistochemistry
Immunohistochemistry was performed on formalin fixed par-
affin-embedded (FFPE) tissue using the avidin-biotin-
peroxidase complex method according to the manufacturer’s
protocol (Vectastain, PK-4004, Vector Laboratories; Burlin-
game, CA, USA). FFPE sections from GBM patients (n D 158)
were immunostained with the following antibodies according
to standard protocols: mouse anti-human cytomegalovirus
clone CCH2C DDG9 detecting IE-1 protein (IR75261-2), rab-
bit anti-human CD3 (A0452, Dako; Carpinteria, CA, USA),
CD4 (NCL¡L-CD4-368, Novocastra), CD8a (M7103, Dako),
and mouse anti-human NKp46 (LS-B2105/10193, BioSite; San
Diego, CA). Human tonsil tissue was used for a positive con-
trol, and primary antibody (MOC-31, sc-52344, Santa Cruz
Biotechnology; Dallas, TX, USA) was used as the negative con-
trol. For IE-1, placental tissue from a known HCMVC patient
was used as the positive control. CD3C,CD4C and CD8C cells
were quantified by morphometry, using NIS-Elements BR v4
software (400 £ magnification, Nikon), and the results were
presented as a percentage of the total number of positive cells
in a minimum of 4 randomly selected fields representing hot
spots for each section analyzed. Tumors were designated posi-
tive or negative for HCMV antigens based on the presence or
absence of immunolabelled cells.
Flow cytometry, HLA A2/B8-dextramer analysis, CTLA-4
checkpoint blockade and cellular immune responses
Frozen peripheral blood mononuclear cells (PBMC) from sero-
typed blood donors (n D 56) and GBM patients (n D 22) were
thawed and used for flow cytometry experiments. Dead cells
were removed from frozen dissociated biopsies (n D 19) before
use in experiments according to the manufacturer’s protocol
(MACS dead cell removal kit, 130-090-101, Miltenyi Biotec;
Bergisch Gladbach, Germany). Cells (6 £ 106) were cultured in
RPMI medium supplemented with 10% human serum (H4522,
Sigma-Aldrich; St. Louis, MO, USA) for 10 h at 37C in 5%
CO2. Cells were divided into 2 groups (3 £ 106 cells/group) and
incubated for 20 min at 4C (1) with anti-CTLA-4 blocking
Table 1. Clinical profile of GBM patients and geographically matched healthy con-
trol donors.
ID Age Gender IgG IgM HLA-A Locus HLA-B Locus
Donor 2 64 M 148.1 0.3 02:01 — 40:01 44:02
Donor 3 63 M 145.8 0.4 02:01 32:01P 18:01 41:01
Donor 4 62 F 0 0.3 01:01 11:01 08:01 35:01
Donor 8 44 M 71.3 0.1 02:01 32:01P 40:01 44:02
Donor 10 24 M 1.7 0.1 02:01 03:01 15:01 ¡
Donor 12 49 M 115.7 0.1 02:01 ¡ 08:01 15:01
Donor 14 33 M 191.8 0.2 02:01 24:02 07:02 15:01
Donor 16 39 M 2.1 0.2 03:01 24:02 08:01 13:02
Donor 19 27 M 39.9 0.1 01:01 24:02 08:01 35:03
Donor 27 41 M 0.3 0.2 02:01 03:01 35:01 40:02
Donor 28 38 F 0.4 0.4 02:01 ¡ 14:02 15:01
Donor 44 29 F 158 0.1 02:01 11:01 40:01 52:01
Donor 49 31 M 0.3 0.2 02:01 11:01 15:01 18:01
Donor 51 39 F 148 0.4 01:01 02:01 08:01 27:05
Donor 52 33 M 0.2 0.3 02:01 ¡ 08:01 40:01
Donor 62 66 F 125.4 0.4 01:01 02:01 08:01 15:01
GBM 1 72 M 0 0 02:01 68:01 27:05 40:01
GBM 2 61 F 0 0 02:01 ¡ 08:01 35:01
GBM 3 49 F 102.9 0.3 01:01 02:11 07:05 57:01
GBM 4 68 F >250 0.7 02:01 — 40:01 57:01
GBM 5 30 M 216.7 0.19 02:01 24:02 07:02 15:01
GBM 6 53 F 1.4 0.1 02:01 03:01 14:02 57:01
GBM 7 61 F 111.4 0.3 01:01 02:01 08:01 27:05
GBM 8 56 M 166 0.1 02:01 11:01 27:05 44:02
GBM 9 67 M 157.9 0.3 02:01 03:01 07:02 40:01
GBM 10 45 F 100.3 0.3 02:01 32:01 07:02 55:01
GBM 11 50 M 107.5 0.2 01:01 24:02 08:01 ¡
GBM 12 46 M 126.2 0.3 01:01 03:01 08:01 40:01
GBM 13 41 F >250 0.4 01:01 11:01 08:01 57:01
GBM 14 84 M ˃250 0.7 01:01 02:01 07:02 15:17
GBM 15 61 F ˃250 0.4 02:01 24:02 07:02 35:01
GBM 16 60 F 246,7 0.2 01:01 02:01 07:02 15:17p
GBM 17 58 M 59 0.4 02:01 03:01 15:01 35:01
GBM 18 72 M 125.5 0.3 02:01 03:01 07:02 44:02
GBM 19 72 M 202,3 0.3 01:01 02:01 08:01 44:02
GBM 20 55 F 87.2 0.1 02:01 24:02 07:02 40:01
GBM 21 43 F 176.3 0.4 24:02 68:01 08:01 44:02
Seropositivity was designated as IgG (Au/mL)  6 and IgM (index)  1.
Table 2. Antibodies used for flow cytometry.
Antibody Company Cat. No.
V450 mouse anti-human CD56 BD Biosciences 560360
V500 mouse Anti-Human CD3 BD Biosciences 560770
PE-CyTM7 mouse anti-human CD8 BD Biosciences 557746
Brilliant Violet 570TM anti-human CD4 Biolegend 300534
Alexa Fluor 700 anti-human CD45 Biolegend 368514
PE anti-HLA-A0201 (NLVPMVATV, pp65) Immudex WB2132-OPT
PE anti- HLA-B0801 (QIKVRVDMV, IE-1) Immudex WI2659-OPT
APC anti-human CD45RO Miltenyi 130-095-460
FITC anti-human CD62L Biolegend 304804
Brilliant Violet 711TM anti-human CD197 (CCR7) Biolegend 353227
Alexa Fluor 488 anti-human IFN-g Biolegend 502515
APC anti-human TNF-a BD Biosciences 340534
Alexa700 mouse anti-human CD28 Biolegend 302920
PE mouse anti-human CD107a BD Biosciences 555801
BV786 mouse anti-human CD152 (CTLA-4) BD Biosciences 563931
FITC anti-human TCR Va24-Ja18 (iNKT) Biolegend 342905
LEAFTM Purified anti-human CD152 (CTLA-4) Biolegend 349903
FITC mouse anti-human cytomegalovirus pp65 Thermo Fisher MA1-7296
PE-CyTM7 mouse anti-human CD31 eBioscience 25-0319-41
PE mouse anti-human CD11b Biolegend 301306
APC mouse anti-human CD279 (PD-1) BD Biosciences 558694







































antibody or isotype control (CD152, 349903, Biolegend; San
Diego, CA, USA) and (2) in media without anti-CTLA-4 anti-
bodies. Half of the cells from each of these groups was subse-
quently stimulated for 12 h with 1 mg/mL of either HLA-A2 or
HLA-B8 specific HCMV peptide (NLVPMVATV and
QIKVRVDMV from pp65 and IE-1, respectively; Table 2).
Lipopolysaccharide (LPS) was added to some samples as a posi-
tive stimulation control. To assess degranulation, CD107a
(560664, BD Biosciences; San Jose, CA, USA) was added to
both groups simultaneously with the peptide and incubated for
1 h. Golgi StopTM and GolgiPlugTM (554724 and 555029, BD
Biosciences) were added according to the manufacturer’s pro-
tocol. After 12 h, cells were aliquoted at 0.25 – 0.5 £ 106 cells/
tube and stained with Live/Dead Fixable Near-IR Dead Cell
Stain Kit (L10119, Thermo Fischer Scientific) and for surface
markers (Table 2) for 20 min at 4C.
The samples were also used for HCMV HLA-A2 and
HLA-B8 dextramer analysis (Table 1 and 2). Cells were
stained with HCMV specific HLA-A2 or HLA-B8 restricted
peptide dextramers (Table 2) as described previously.72 Fluo-
rescent Minus One (FMO) controls were used for each
channel, and lymphocytes were gated as indicated (Fig. S1A
and Fig. S3A). Within the CD3C CD56¡ T cell gate, CD8C
and CD4C na€ıve (N), central memory (CM), effector (E) and
effector memory (EM) T cells were distinguished based on
expression of CD45RO, CD62L and CCR7 (Table 2, Fig. 3B
and 3C). Data was acquired on the LSR FortessaTM (BD Bio-
sciences) and analyzed using FlowJo, version 10 (Tree Star
Inc.; Ashland, OR, USA).
ELISpot
Functional T cell responses against HLA-A2 and HLA-B8-
bound HCMV peptides were verified in an IFNg enzyme linked
immunospot assay (ELISpotPRO, 3420–4AST-2, Mabtech;
Mariemont, OH, USA). Cryopreserved PBMCs and biopsies
were recovered and treated as described for flow cytometry
assays. After 10 hours of incubation (as described for flow
cytometry assays), cells were divided into 2 groups (1) incu-
bated for 20 min at 4C with anti-CTLA-4 blocking antibody
(CD152, 349903, Biolegend; San Diego, CA, USA) or (2) cells
that were not blocked. 0.25 £ 106 ¡0.5 £ 106 cells from each
group were added to each ELISpot well according to manufac-
turer’s protocol. Cells in triplicate wells were stimulated with
1 mg/mL of either HLA-A2 or HLA-B8 specific HCMV peptide
while one group was left untreated in medium for the non-
stimulation control. Anti-CD3 antibody provided by manufac-
turer was used as a positive stimulation control to confirm the
viability of cells. After 12 h of incubation at 37C in 5% CO2,
ELISpot membranes were developed, scanned and quantified as
described previously.72 IFNg secretion was considered positive
when the number of cells secreting IFNg was ˃ 0 total cells.
MGMT methylation analysis
Tumor DNA (200 ng) was treated with sodium bisulfite using
the EZ DNA Methylation-Gold KitTM (D5005, Zymo
Research; Irvine, CA, USA). PCR was performed on treated
DNAs at 40 cycles with primers specific for methylated or













(n D 9) (n D 7) (n D 17) (n D 2) (n D 13) (n D 2) Statistical analysis
% of CD4CEM 30.1§ 5.1 18.7 § 1.2 42.3 § 5.1 25.2 62.1 § 4.1 70.7 Two-way ANOVA, Bonferroni’s multiple comparison test:
P < 0.01 for Donor HCMVC vs. patient HCMV¡ biopsy,
P < 0.0001 for Donor HCMVC vs. patient HCMVC biopsy,
P < 0.0001 for Donor HCMV¡ vs. patient HCMV¡ biopsy,
P < 0.0001 for Donor HCMV¡ vs. patient HCMVC biopsy,
P < 0.01 for Donor HCMV¡ vs. patient HCMVC PBMC,
P < 0.05 patients’ HCMV¡ PBMC vs. patient HCMV¡ biopsy
P < 0.01 patients’ HCMVC PBMC vs. patient HCMVC biopsy
and
P < 0.01 patients’ HCMV¡ PBMC vs. patient HCMVC biopsy
% of CD4CN 36.6§ 5.1 44.9 § 2.1 19.4 § 3.8 27.7 5.2 § 1.9 4.1 Two-way ANOVA, Bonferroni’s multiple comparison test:
P < 0.05 for Donor HCMVC vs. patient HCMV¡ biopsy,
P < 0.001 for Donor HCMVC vs. patient HCMVC biopsy,
P < 0.05 for Donor HCMVC vs. patient HCMV¡ biopsy,
P < 0.01 for Donor HCMV¡ vs. patient HCMV¡ biopsy,
P < 0.0001 for Donor HCMV¡ vs. patient HCMVC biopsy
and
P < 0.001 for Donor HCMV¡ vs. patient HCMVC PBMC
% of CD8CEM 25.9§ 4.2 16.6 § 3.5 28.1 § 4.1 22.1 52.1 § 5.6 54.0 Two-way ANOVA, Bonferroni’s multiple comparison test:
P < 0.001 for Donor HCMVC PBMC vs. patient HCMVC
biopsy, P < 0.05 for Donor HCMV¡PBMC vs. patient
HCMV¡ biopsy,
P < 0.0001 for Donor HCMV¡PBMC vs. patient HCMVC
biopsy and
P < 0.0001 for patients’ HCMVC biopsy vs. patient HCMVC
PBMC
% of CD8CN 26.9§ 5.7 40.60 § 5.5 26.9 § 4.4 21.1 10.9 § 2.8 0.8 Two-way ANOVA, Bonferroni’s multiple comparison test :
P < 0.01 for Donor HCMV¡PBMC vs. patient HCMV¡ biopsy
and P < 0.001 for Donor HCMV¡PBMC vs. patients
HCMVC biopsy






































unmethylated MGMT promoter sequences. PCR products were
separated on 2% agarose gels, and images of ethidium bro-
mide-stained bands were acquired. The primer sequences used
were the following: unmethylated MGMT promoter forward,
50-TTTGTGTTTTGATGTTGTTAGGTTTTTGT-30 and
reverse, 50-AACTCCACACTC TTCCAAAAACAAAACA-30;
methylated MGMT promoter forward, 50-TTTCGACGTTCG-
TAGGTTTTCGC-30 and reverse, 50-GCACTCTTCCGAAAAC
GAAACG-30.
Statistical analysis
Patient survival was analyzed using the Kaplan-Meier method
(42), and Cox-proportional hazards regression was used to assess
significant differences in survival adjusted for age, sex, and
MGMT as possible confounders. The Fisher’s exact test was
used to compare frequency differences between HCMVC and
HCMV¡ patient and healthy donor cohorts. A 2-way ANOVA
with Bonferoni correction for multiple testing was used to com-
pare > 2 categorical variables in more than 2 dependent varia-
bles. Descriptive statistics were reported as the mean § SEM
unless otherwise stated. Two-sided P-values < 0.05 were consid-
ered significant. Statistical analyses were performed in Stata ver-
sion 13.1 (College Station, TX, USA) or Graphpad PRISM 6.0
software (La Jolla, CA, USA). Venn diagrams were generated in
RStudio Software, version 1.0.136 (Boston, MA, USA).
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